In the past decade, more and more genetic variants such as GCKR, TRIB1, TM6SF2, APOE, PNPLA3, HSD17B13, etc. have been discovered, which regulate the susceptibility and progression of MAFLD by affecting lipid metabolism, inflammatory response, insulin resistance, oxidative stress, liver fibrosis and other processes. Here, PNPLA3 is linked to Hepatic fibrosis.